GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $83.84 $93.35 Friday, 19th Apr 2024 BMRN stock ended at $88.63. This is 1.60% less than the trading day before Thursday, 18th Apr 2024. During the day the stock fluctuated 2.14% from a day low at $88.29 to a day high of $90.18.
90 days $83.44 $94.51
52 weeks $76.02 $99.55

Historical BioMarin Pharmaceutical Inc. prices

Date Open High Low Close Volume
2023-02-08 $110.59 $111.79 $109.72 $110.44 834 219
2023-02-07 $112.03 $112.03 $109.90 $111.31 1 686 353
2023-02-06 $111.80 $112.98 $110.78 $112.18 868 869
2023-02-03 $113.26 $113.97 $111.59 $112.20 1 062 620
2023-02-02 $116.64 $116.70 $111.85 $112.84 1 758 450
2023-02-01 $115.05 $116.86 $114.25 $116.71 1 576 097
2023-01-31 $115.00 $115.59 $114.55 $115.35 1 237 394
2023-01-30 $116.62 $117.49 $114.61 $114.70 1 516 452
2023-01-27 $117.00 $117.77 $116.81 $117.27 1 217 204
2023-01-26 $116.00 $117.11 $115.03 $116.98 1 336 524
2023-01-25 $114.60 $116.59 $114.39 $116.03 2 450 322
2023-01-24 $111.45 $114.02 $111.26 $113.82 1 202 216
2023-01-23 $110.40 $111.55 $110.20 $111.45 1 173 358
2023-01-20 $109.47 $111.03 $109.29 $110.75 1 338 400
2023-01-19 $110.47 $110.47 $109.10 $109.20 1 148 300
2023-01-18 $111.31 $112.05 $110.33 $110.69 1 107 348
2023-01-17 $111.55 $112.99 $111.02 $111.75 1 554 900
2023-01-13 $112.25 $114.80 $111.87 $112.72 1 582 120
2023-01-12 $110.50 $113.65 $110.01 $113.57 1 723 544
2023-01-11 $111.23 $112.70 $109.14 $111.15 1 699 156
2023-01-10 $107.26 $111.97 $106.99 $111.40 2 864 771
2023-01-09 $109.83 $110.25 $105.95 $107.10 2 526 703
2023-01-06 $108.17 $109.29 $106.90 $108.71 2 205 800
2023-01-05 $107.00 $107.59 $105.77 $106.86 1 794 348
2023-01-04 $103.69 $106.93 $102.26 $106.92 2 710 984
Click to get the best stock tips daily for free!

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical. BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o... BMRN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT